Searchable abstracts of presentations at key conferences on calcified tissues
Previous issue | Volume 3 | ECTS2014 | Next issue

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

Card image cap
European Calcified Tissue Society Annual Congress, 17 - 20 May 2014; Prague, Czech Republic

Clinical Update

Postmenopausal osteoporosis, vitamins and minerals

ba0003cu1.2 | Postmenopausal osteoporosis, vitamins and minerals | ECTS2014

Selenium

Williams Graham

Selenium (Se) is an essential trace element active in the catalytic sites of many redox enzymes, including glutathione peroxidase and the iodothyronine deiodinases that metabolize thyroid hormones. In humans 25 genes encode selenoproteins, in which a specific tRNA incorporates the amino acid selenocysteine during protein translation. Although specific roles for many selenoproteins are unclear, studies suggest an important role for Se in skeletal development and bone maintenanc...

ba0003cu1.3 | Postmenopausal osteoporosis, vitamins and minerals | ECTS2014

Vitamin K and bone health

Vermeer Cees

Vitamin K is a group name for a number of closely related compounds. Relevant structures for this presentation are phylloquinone (vitamin K1), menaquinone-4 (MK-4) and MK-7. The latter two are members of the vitamin K2 family. The function of all forms of vitamin K is to catalyze the formation of Gla-residues, which are strong calcium-binding groups and essential for the activity of the proteins in which they occur. For calcium metabolism three Gla-proteins are of particular i...

ba0003cu1.5 | Postmenopausal osteoporosis, vitamins and minerals | ECTS2014

Treatment of postmenopausal osteoporosis: long-term benefit and risk

Abrahamsen Bo

Effective treatments are available to reduce fracture risk in patients with postmenopausal osteoporosis. Though factors have been identified that modify the effect of treatment with one or more the currently available drugs, as a rule patients will benefit more from treatment the higher their base risk of fracture. From a societal and clinical point of view it is surprising that many guidelines for postmenopausal osteoporosis do not target treatment to patients at the highest ...